| 1.84 -0.075 (-3.92%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.25 |
1-year : | 2.55 |
| Resists | First : | 1.92 |
Second : | 2.19 |
| Pivot price | 1.82  |
|||
| Supports | First : | 1.5 |
Second : | 1.24 |
| MAs | MA(5) : | 1.96 |
MA(20) : | 1.8 |
| MA(100) : | 2.36 |
MA(250) : | 2.44 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 66.6 |
D(3) : | 76.1 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 8.07 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BTAI ] has closed below upper band by 48.5%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.97 - 1.99 | 1.99 - 1.99 |
| Low: | 1.81 - 1.83 | 1.83 - 1.84 |
| Close: | 1.82 - 1.84 | 1.84 - 1.86 |
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Thu, 15 Jan 2026
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - FinancialContent
Thu, 15 Jan 2026
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
Mon, 12 Jan 2026
BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz
Mon, 12 Jan 2026
Drugmaker taps veteran to pursue at-home treatment for bipolar agitation - Stock Titan
Wed, 12 Nov 2025
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 2.13e+007 (%) |
| Held by Institutions | 4.2 (%) |
| Shares Short | 1,580 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.014e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 320.4 % |
| Return on Equity (ttm) | -67.4 % |
| Qtrly Rev. Growth | 752000 % |
| Gross Profit (p.s.) | -258.1 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.00952e+006 |
| Qtrly Earnings Growth | -9.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.09 |
| Dividend | 0 |
| Forward Dividend | 979750 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|